Shares of Amgen Inc. AMGN shed 2.39% to $306.86 Tuesday, on what proved to be an all-around favorable trading session for the ...

Merck & Co. will pay as much as $2 billion for the rights to Jiangsu Hengrui Pharmaceuticals Co.’s experimental heart drug, ...

SCHD's Index reconstituted at the close of business Friday, resulting in 20 additions and 17 deletions. See why I rate the ...

The Mayo Clinic and Xact Sciences are developing an easy, noninvasive test to detect endometrial cancer in women with ...

Big Pharma is expected to see big returns from its investment in a class of drugs made famous by Novo Nordisk’s (NVO) popular ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

Shares of Amgen Inc. (NASDAQ:AMGN – Get Free Report) have earned a consensus recommendation of “Hold” from the twenty-four ...

Piper Sandler analyst David Amsellem reiterated a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $329.00. The ...

We recently published a list of 13 Best Healthcare Dividend Stocks to Invest in. In this article, we are going to take a look ...

AbbVie’s Humira was the top-selling drug in the world for many years. Now, its sales are eroding as doctors switch to ...

Amgen (AMGN) ended the recent trading session at $314.38, demonstrating a -0.53% swing from the preceding day's closing price. The stock trailed the S&P 500, which registered a daily gain of 1.77%.

Amgen Inc. urged a federal judge to overturn a jury’s $50.3 million verdict for its leukemia drug Blincyto’s infringement of ...